ProQR Therapeutics N.V. Ordinary Shares (PRQR)
Stock · NASDAQ · Health Care
$2.29as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$1.41
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $241.32M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
ProQR Therapeutics N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PRQRProQR Therapeutics N.V. Ordinary Shares$2.29▼ 1.29%Market cap $241.32MP/E —
- MGNXMacroGenics Inc. Common Stock$4.13▲ 1.23%Market cap $242.81MP/E —$1.29$5.08
- ADAGAdagene Inc. American Depositary Shares$3.68▼ 5.64%Market cap $239.77MP/E —$1.3$4.85
- SLGLSol-Gel Technologies Ltd. Ordinary Shares$69.41▼ 4.35%Market cap $230.38MP/E —$21$97.97
- VRXAVeraxa Biotech AG Ordinary Shares$1.36▼ 5.56%Market cap $258.78MP/E —$1.32$27.36
- ALXOALX Oncology Holdings Inc. Common Stock$2▼ 2.44%Market cap $259.71MP/E —$0.96$2.66
- ELDNEledon Pharmaceuticals Inc. Common Stock$3.19▼ 3.92%Market cap $264.75MP/E —$1.35$4.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $241.32M | — | $2.29 | ▼ 1.29% | |
| MGNX MacroGenics Inc. Common Stock | $242.81M | — | $4.13 | ▲ 1.23% | $1.29$5.08 |
| ADAG Adagene Inc. American Depositary Shares | $239.77M | — | $3.68 | ▼ 5.64% | $1.3$4.85 |
| SLGL Sol-Gel Technologies Ltd. Ordinary Shares | $230.38M | — | $69.41 | ▼ 4.35% | $21$97.97 |
| VRXA Veraxa Biotech AG Ordinary Shares | $258.78M | — | $1.36 | ▼ 5.56% | $1.32$27.36 |
| ALXO ALX Oncology Holdings Inc. Common Stock | $259.71M | — | $2 | ▼ 2.44% | $0.96$2.66 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $264.75M | — | $3.19 | ▼ 3.92% | $1.35$4.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other CatalystsSeekingAlpha · 8/21/2026
- Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga · 8/20/2026
- B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8Benzinga · 8/20/2026
- Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue EstimatesYahoo · 8/14/2026
- ProQR Announces Second Quarter 2026 Operating and Financial ResultsYahoo · 8/13/2026
- ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M EstimateBenzinga · 8/13/2026
- ProQR Form4 Filing Shows CEO Daniel De Boer Buys 200,000 Shares At An Average Price Of $1.77; Increasing Direct Holdings to 500,000 SharesBenzinga · 8/3/2026
Insider Activity
Insider Actions →Acquired
664.5K
Disposed
0
- de Boer Daniel Anton · July 31, 2026 · Buy200.0K @ $1.77
- Bart Filius · July 17, 2026 · Buy150.0K @ $1.72
- de Boer Daniel Anton · July 9, 2026 · Buy150.0K @ $1.74
- de Boer Daniel Anton · July 7, 2026 · Buy150.0K @ $1.59
- Hinsch Gylvin Lykke · June 2, 2026 · Grant14.5K
See the full, filterable feed with live charts on the MarketWall dashboard.